(Q38223072)

31 August 2017

title

Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease (English)

1 reference

31 August 2017

1 reference

Michele A Faulkner

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

24 June 2014

1 reference

Expert Opinion on Drug Safety

31 August 2017

published in

1 reference

31 August 2017

volume

13

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

1055-1069

1 reference

Adverse effects of antiparkinsonian drugs

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Clinical management of neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

21 January 2018

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Toxicology and safety of COMT inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Continuous dopaminergic therapy in Parkinson disease: time to stride back?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Levodopa-induced dyskinesia: review, observations, and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Tolcapone: an efficacy and safety review (2007)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Dopamine agonists in the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Comparative tolerability of the newer generation antiparkinsonian agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Recent developments in the pharmacological treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Quick titration of pergolide in cotreatment with domperidone is safe and effective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson???s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Drug safety evaluation of rotigotine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

A review of the receptor-binding and pharmacokinetic properties of dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Dopamine receptor agonists in the therapy of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Valvular heart disease in patients taking pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Fibrotic valvular heart disease subsequent to bromocriptine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Fibrosis associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Sleep attacks in patients taking dopamine agonists: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Sociocultural differences in gait

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Waking up to sleep episodes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Pathological gambling caused by drugs used to treat Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease--a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Excessive daytime somnolence in Japanese patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Effects of pramipexole on the processing of rewarding and aversive taste stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Pathological gambling associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Selegiline as initial treatment in de novo parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Safety of rasagiline for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Tyramine pharmacokinetics and reduced bioavailability with food

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Safety and tolerability of COMT inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Effects of 3-OM-dopa on monoamine metabolism in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

The rise and fall of tolcapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Control of respiration and ATP synthesis in mammalian mitochondria and cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Effects of entacapone and tolcapone on mitochondrial membrane potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Uncouplers of oxidative phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Entacapone-induced hepatotoxicity and hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

The problems of anticholinergic adverse effects in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Cognitive impairments and depression in Parkinson's disease: a follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Skin cancer and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Levodopa therapy and malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Clinical Characteristics of Pramipexole-Induced Peripheral Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2014.931369

10.1517/14740338.2014.931369

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference